Mycoplasma & Stealth Infections: Chronic Fatigue Adelaide
Quick Answer
Mycoplasma species are cell-wall-deficient bacteria that may persist inside host cells, evading immune detection and resisting standard beta-lactam antibiotics. In susceptible individuals, chronic Mycoplasma infection has been associated with mitochondrial dysfunction, elevated pro-inflammatory cytokines (IL-6, TNF-alpha), and molecular mimicry — processes that may contribute to the fatigue, widespread pain, and cognitive symptoms characteristic of chronic fatigue syndrome (CFS) and fibromyalgia (1,2,3,4,15).
At a Glance
- Mycoplasma species such as M. pneumoniae, M. fermentans, and M. hominis lack a cell wall, enabling intracellular persistence and immune evasion (1,2).
- Garth Nicolson’s research identified Mycoplasma infections in up to 52% of CFS/fibromyalgia patients tested by PCR (3,8).
- Molecular mimicry triggered by Mycoplasma antigens may drive autoimmune-like neuroinflammation and central sensitisation (3,8,9).
- Mitochondrial electron transport chain impairment from Mycoplasma metabolic parasitism may reduce ATP production and contribute to persistent fatigue (4,7).
- Standard serology often misses chronic Mycoplasma infections; PCR-based testing and cytokine profiling may improve detection rates (10,12).
- Functional medicine strategies combining botanical antimicrobials, biofilm disruption, and mitochondrial support may complement conventional treatment approaches (13,14,15).
For many people in Adelaide living with the invisible pain of fibromyalgia or the persistent exhaustion of chronic fatigue syndrome (CFS), standard investigations often fail to reveal a clear explanation. In some cases, underlying biological contributors may include persistent, difficult-to-detect infections. Mycoplasma species — classified within the class Mollicutes — represent a unique class of bacteria capable of evading immune surveillance and altering cellular metabolism, potentially contributing to chronic multisystem illness.
The Biology of a Stealth Infection
Mycoplasma pneumoniae, M. hominis, and M. fermentans (incognitus strain) lack a rigid peptidoglycan cell wall, making them the smallest self-replicating organisms known to microbiology (1,5). Their pleomorphic nature allows them to adapt shape and infiltrate diverse tissues, including synovial fluid, respiratory epithelium, and the central nervous system.
| Mechanism | Description | Clinical Relevance |
|---|---|---|
| Metabolic parasitism | Mycoplasma species cannot synthesise cholesterol or fatty acids and acquire these from host cell membranes (4,6) | May destabilise cellular membrane integrity and impair signal transduction |
| Mitochondrial interference | Competition for nutrients and generation of reactive oxygen species (ROS) may impair electron transport chain complexes I-IV (7,11) | May reduce ATP availability, contributing to persistent fatigue and exercise intolerance |
| Immune evasion | Intracellular location and antigenic variation allow evasion of IgG and IgM antibody detection (1,5) | Standard serology may return false-negative results in chronic infection |
Molecular Mimicry and Fibromyalgia Pain
Garth Nicolson and colleagues at the Institute for Molecular Medicine demonstrated that persistent exposure to Mycoplasma antigens may trigger molecular mimicry, a process in which immune responses directed at microbial lipoproteins cross-react with host neural and connective tissues (3,8). Aristo Vojdani’s PCR-based research further confirmed elevated Mycoplasma detection rates in CFS cohorts compared to healthy controls (8). In certain individuals, this immune cross-reactivity may contribute to:
- Neuro-inflammation: associated with microglial activation, cognitive dysfunction, sensory sensitivity, and “fibro-fog” (8,14).
- Central sensitisation: a state of heightened dorsal horn and cortical nervous system reactivity that amplifies pain perception, as described by Jo Nijs and colleagues at Vrije Universiteit Brussel (9,15).
Advanced Diagnostic Testing in Adelaide
Standard antibody-based Mycoplasma serology may fail to detect persistent infections due to intracellular immune evasion and variable IgG/IgM antibody responses (10,12). In a functional medicine setting, Rohan Smith at Elemental Health and Nutrition may consider additional markers when clinically appropriate:
| Test Type | What It Measures | Clinical Application |
|---|---|---|
| Advanced PCR testing | Direct detection of Mycoplasma DNA via polymerase chain reaction (10,12) | Identifies active or persistent infection missed by serology |
| Cytokine profiling | Inflammatory mediators including IL-6, TNF-alpha, and interferon-gamma (11,13) | May reflect chronic Th1/Th2 immune activation patterns |
| Mitochondrial dysfunction assessment | Organic acid markers of electron transport chain function and oxidative stress | Evaluates downstream metabolic burden associated with chronic infection |
Supportive Botanical and Nutritional Strategies
Addressing persistent intracellular infections often requires more than antimicrobial suppression alone, as Robert Naviaux’s cell danger response (CDR) research at UC San Diego has highlighted (14). Functional medicine approaches emphasise restoring host resilience alongside pathogen-targeted strategies. Supportive protocols may include:
| Strategy | Key Components | Proposed Mechanism |
|---|---|---|
| Biofilm support | Enzymes (nattokinase, serrapeptase) and N-acetylcysteine (NAC) | May assist in disrupting microbial protective extracellular matrices (12,15) |
| Intracellular botanical support | Isatis tinctoria, Cryptolepis sanguinolenta, Houttuynia cordata | In vitro and preclinical research suggests antimicrobial activity against Mycoplasma species (13,14) |
| Mitochondrial support | CoQ10, phosphatidylcholine, NT Factor lipid replacement therapy | Targeted nutrients aimed at restoring membrane integrity and ATP production (7,15) |
Next Steps
- Consider advanced testing: If standard investigations have not explained your fatigue or pain, PCR-based testing and cytokine profiling may help identify persistent stealth infections as a contributing factor.
- Assess mitochondrial function: An organic acids test (OAT) can reveal markers of mitochondrial stress and oxidative burden that may be driving energy depletion.
- Explore integrative support: A personalised protocol combining botanical antimicrobials, biofilm disruption, and mitochondrial nutrients may support recovery alongside conventional care.
Frequently Asked Questions
Key Insights
- Mycoplasma species are cell-wall-deficient bacteria within the class Mollicutes, capable of intracellular persistence (1,2)
- They have been associated with mitochondrial electron transport chain stress and reduced ATP production in some individuals (4,7)
- Molecular mimicry triggered by Mycoplasma lipoproteins may contribute to immune-mediated pain and neurological symptoms (3,8)
- PCR-based detection methods developed by researchers including Vojdani and Nicolson may improve diagnostic sensitivity over standard serology (8,10)
- Effective care focuses on immune balance, metabolic support, and host resilience rather than pathogen eradication alone
Citable Takeaways
- Mycoplasma species lack a peptidoglycan cell wall, enabling them to evade beta-lactam antibiotics and persist intracellularly, according to Razin et al. in Microbiological and Molecular Biology Reviews (1998) (1).
- Nicolson and colleagues found Mycoplasma infections in a significant proportion of chronic fatigue syndrome and fibromyalgia patients using PCR-based detection methods (3).
- Mycoplasma metabolic parasitism may impair mitochondrial electron transport chain function and reduce cellular ATP production, as Nicolson described in lipid replacement therapy research (7).
- Vojdani et al. detected Mycoplasma genus DNA by PCR in patients with chronic fatigue syndrome at rates significantly higher than healthy controls (8).
- Nijs and colleagues at Vrije Universiteit Brussel identified central sensitisation as a key mechanism amplifying pain perception in chronic fatigue and fibromyalgia patients (9,15).
- Naviaux’s cell danger response model proposes that persistent intracellular infection may trigger a metabolic shift that maintains chronic illness even after pathogen clearance (14).
Reclaiming Energy and Resilience
For individuals experiencing persistent fatigue or widespread pain without clear explanations, investigating contributory biological factors such as stealth infections may provide additional insight. At Elemental Health and Nutrition, we use a personalised, systems-based approach to identify and address the physiological patterns underlying chronic illness — including advanced testing for stealth pathogens, mitochondrial function, and immune activation.
References
- Razin S et al. Molecular biology and pathogenicity of mycoplasmas. Microbiol Mol Biol Rev. 1998 Dec;62(4):1094-156. https://doi.org/10.1128/MMBR.62.4.1094-1156.1998
- Baseman JB, Tully JG. Mycoplasmas: sophisticated, reemerging, and burdened by their notoriety. Emerg Infect Dis. 1997 Jan-Mar;3(1):21-32. https://doi.org/10.3201/eid0301.970104
- Nicolson GL et al. Mycoplasmal infections in chronic fatigue syndrome, fibromyalgia, and autoimmune diseases. J Chronic Fatigue Syndr. 1998;4(3):3-22. https://doi.org/10.1300/J092v04n03_02
- Rottem S. Interaction of mycoplasmas with host cells. Physiol Rev. 2003 Apr;83(2):417-32. https://doi.org/10.1152/physrev.00030.2002
- Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev. 2004 Oct;17(4):697-728. https://doi.org/10.1128/CMR.17.4.697-728.2004
- Razin S. The cell membrane of mycoplasma. Ann N Y Acad Sci. 1967 Jul 31;143(1):5-24. https://doi.org/10.1111/j.1749-6632.1967.tb27648.x
- Nicolson GL. Lipid replacement therapy: a natural medicine approach to replacing damaged lipids in cellular membranes and organelles and restoring mitochondrial function. J Am Nutraceutical Assoc. 2003;6(3):22-33.
- Vojdani A et al. Detection of Mycoplasma genus and species by PCR in patients with chronic fatigue syndrome. J Clin Lab Immunol. 1998;50(1):1-10. https://pubmed.ncbi.nlm.nih.gov/10392637/
- Nijs J et al. Chronic fatigue syndrome: exercise performance related to immune dysfunction. Clin Rheumatol. 2006 Mar;25(2):153-60. https://doi.org/10.1007/s10067-005-1161-4
- Endresen GK. Mycoplasma blood infection in chronic fatigue and fibromyalgia syndromes. Rheumatol Int. 2003 Sep;23(5):211-5. https://doi.org/10.1007/s00296-002-0272-5
- Lo SC et al. Pathogenicity of Mycoplasma fermentans (incognitus strain). Am J Trop Med Hyg. 1991;44(4):391-8. https://doi.org/10.4269/ajtmh.1991.44.391
- Waites KB et al. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev. 2017 Jul;30(3):747-809. https://doi.org/10.1128/CMR.00114-16
- Feng J et al. Identification of essential genes for Mycoplasma pneumoniae survival. Front Microbiol. 2019 May 7;10:1025. https://doi.org/10.3389/fmicb.2019.01025
- Naviaux RK. Metabolic features of the cell danger response. Mitochondrion. 2014 May;16:7-17. https://doi.org/10.1016/j.mito.2013.08.006
- Nijs J et al. Treatment of central sensitization in patients with ‘unexplained’ chronic pain: an update. Expert Opin Pharmacother. 2011 Dec;12(18):2891-905. https://doi.org/10.1517/14656566.2011.628658
